Renzenbrink & Partner has advised funds advised by IK Partners on the sale of all shares in Klingel Holding GmbH (Klingel Medical Group) to the listed Swedish Elos Medtech AB, a portfolio company of TA Associates. The purchase price will be financed by a capital increase of Elos Medtech AB, which is guaranteed by TA Associates (backstop). <\/p>\n\n
The Klingel Medical Group is one of the leading manufacturers of metal products for medical technology and a specialist in the precision machining of high-strength materials Klingel employs around 900 people at its headquarters in Pforzheim and at its partner companies Josef Ganter Feinmechanik in Dauchingen, puracon in Rosenheim, B\u00e4chler Feintech in H\u00f6lstein and Matzingen and Ruetschi in Renquishausen (southern Germany), Muntelier and Yverdon-les-Bains (both in Switzerland).<\/p>\n\n
Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopaedic implants and instruments. The company has sites in Sweden, Denmark, China and the USA. The customer base includes international medical technology companies. <\/p>\n\n
Renzenbrink & Partner had already advised IK Partners on the acquisition of Klingel Medical Group and all add-ons. Now Renzenbrink & Partner provided comprehensive legal and tax advice on the sale process. The Renzenbrink & Partner team consisted of Dr. Ulf Renzenbrink, LL.M.<\/a> (Corporate\/PE), Marc Holger Kotyrba <\/a>(Tax\/PE) Dr. Andreas Stoll, LL.M. <\/a>(Corporate\/PE), Dr. Alexander Haunschild<\/a>, Moritz Rojek<\/a> (both Corporate\/PE) as well as Dr. Toufic Schilling<\/a> and Marie Eikmeier<\/a> (both Tax\/PE). <\/p>\n\n <\/p>\n","protected":false},"featured_media":2077,"template":"","class_list":["post-798","deals","type-deals","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n